

C-3169/1/US

99/451,641

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant

Gao, D. et al.

Filing Date

November 30, 1999

Group No.

1615

U.S. PATENT DOCUMENTS

Examiner Initial*		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
B	AC	5,869,096	Feb 9, 1999	Barclay et al.	424	468	Dec 9, 1994
	AD	5,756,529	May 26, 1998	Isakson et al.	514	406	
	AE	5,633,272	May 27, 1997	Talley et al.	514	378	
	AF	5,474,784	Dec 12, 1995	Stevens et al.	424	456	
	AG	5,342,624	Aug 30, 1994	McNeill et al.	424	451	
	AH	4,866,848	Sep 12, 1989	Conte et al.	424	466	
S	AI	4,681,755	Jul 21, 1987	Colombo et al.	424	486	

FOREIGN PATENT DOCUMENTS

Examiner Initial*		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
	BC	WO 97/44028	Nov 27, 1997	WIPO	A61K	31/365		X
	BD	WO 99/09988	Mar 4, 1999	WIPO	A61K	31/54		X

OTHER DOCUMENTS (Including author, title, date, pertinent pages, etc.)

	CD	Abdou (1989). Dissolution, Bioavailability and Bioequivalence, pp. 58-66, 457-458. Mack Publishing Co.
	CE	American Pharmaceutical Association (1986). Handbook of Pharmaceutical Excipients, pp. 1-2, 5, 9-11, 26-33, 39-40, 45-48, 53-58, 93-98, 113-115, 119-121, 123-126, 128-129, 134-135, 138-140, 153-162, 166-169, 177-183, 209-211, 214-215, 234-239, 261-262, 266-268, 271-272, 275-278, 284-293, 298-300, 304-308
	CF	Anon. (1997). Drugs of the Future 22(7). Section headed "Pharmacokinetics", p. 713.
	CG	Ayanoglu (1981). Biyofarmasötik ve Klinik Farmakokinetik (In Turkish; believed to translate as "Biopharmaceutics and Clinical Pharmacokinetics"), pp. 35-36. No English translation available.
	CH	Bandelin (1989). Compressed tablets by wet granulation. In Lieberman et al. (ed.) Pharmaceutical Dosage Forms: Tablets, 2nd ed., Vol. 1, pp. 131-193. Marcel Dekker.
	CI	Banker & Anderson (1986). Tablets. In Lachman et al. (ed.) The Theory and Practice of Industrial Pharmacy, pp. 293-373. Lea & Febiger.
	CJ	DiSanto (1985). Bioavailability and Bioequivalency Testing. Chap. 77 in Remington's Pharmaceutical Sciences, 17th ed., pp. 1424-1431. Mack Publishing Co.
	CK	Geçgil (1991). Farmasötik Teknolojiye Başlangıç (In Turkish; believed to translate as "Introduction to Pharmaceutical Technology"), pp. 346-348. No English translation available.
	CL	Güven (1979). İlaç Endüstrisi Teknolojisi (In Turkish; believed to translate as "Drug Industry Technology"), pp. 67-81. No English translation available.
	CM	Hubbard et al. (1998). Efficacy, tolerability and safety of celecoxib in osteoarthritis. American College of Rheumatology 62nd National Scientific Meeting, San Diego, California, November 1998.
	CN	Igzü (date unknown). Genel ve Endüstriyel Farmasötik Teknoloji (In Turkish; believed to translate as "General and Industrial Pharmaceutical Technology"), Vol. 1, pp. 367-382. No English translation available.
	CO	Igzü (1983). Genel -- Endüstriyel Farmasötik Teknoloji -- II (In Turkish; believed to translate as "General and Industrial Pharmaceutical Technology -- II"), pp. 211-241. No English translation available.


Examiner

Date Considered

*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP §609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)



Applicant

Gao, D. et al.

Filing Date

November 30, 1999

Group No.

1615

OTHER DOCUMENTS (Including author, title, date, pertinent pages, etc.)

- CP Karim *et al.* (1997). SC-58635 (celecoxib): a highly selective inhibitor of cyclooxygenase-2. Disposition kinetics in man and identification of its major CYP450 isozyme in its biotransformation. *Pharmaceutical Research* 14, p. S-617, Abstr. 3469.
- CQ Kayaalp (date unknown). *Tibbi Farmakoloji* (In Turkish, believed to translate as "Medicinal Pharmacology"). Vol. 1, pp. 27-28 and Vol. 2, p. 1050. No English translation available.
- CR Lane (1997). Pain management in osteoarthritis: the role of COX-2 inhibitors. *Journal of Rheumatology* 24 (Supp. 49), 20-24.
- CS Parnham (1996). Inflammation: mechanisms and therapeutics. *Drug News & Perspectives* 9, 631-639.
- CT Peck *et al.* (1989). Tablet formulation and design. In Lieberman *et al.* (ed.) *Pharmaceutical Dosage Forms Tablets*, 2nd ed., Vol. 1, pp. 75-130. Marcel Dekker.
- CU Proudfoot (1990). Factors influencing bioavailability: factors influencing drug absorption from the gastrointestinal tract. In Aulton (ed.) *Pharmaceutics, The Science of Dosage Form Design*, p. 156.
- CV Rubinstein (1990). Tablets. In Aulton (ed.) *Pharmaceutics, The Science of Dosage Form Design*, pp. 304-321.
- CW Shangraw (1989). Compressed tablets by direct compression. In Lieberman *et al.* (ed.) *Pharmaceutical Dosage Forms: Tablets*, 2nd ed., Vol. 1, pp. 195-246. Marcel Dekker.
- CX Wacke *et al.* (1989). Preformulation testing. In Lieberman *et al.* (ed.) *Pharmaceutical Dosage Forms Tablets*, 2nd ed., Vol. 1, pp. 1-73. Marcel Dekker. See pp. 5, 47-48.
- CY Welling *et al.* (1991). *Pharmaceutical Bioequivalence*, pp. 413-414. Marcel Dekker.

Examiner

Date Considered

6/10/02

* Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP §609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED
MAY 02 2002
TECH CENTER 1600/2900

C-3169/1/US

09/451,641

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant

Gao, D. et al.

Filing Date

Group No

November 30, 1999

1615

U.S. PATENT DOCUMENTS

Examiner Initial*		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
		AJ 6,040,850	Apr 11, 2000	Young et al.	514	183	Jul 7, 1995
		AK 5,932,576	Aug 3, 1999	Anantanarayan et al.	514	235.5	May 22, 1998
		AL 5,739,166	Apr 14, 1998	Reitz et al.	514	602	
		AM 5,643,933	Jul 1, 1997	Talley et al.	514	372	
		AN 5,540,669	Jul 30, 1996	Sage et al.	604	290	
		AO 5,474,995	Dec 12, 1995	Ducharme et al.	514	241	
		AP 4,865,849	Sep 12, 1989	Conte et al.	424	466	

FOREIGN PATENT DOCUMENTS

Examiner Initial*		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
		BE WO 95/00501	Jan 5, 1995	WIPO	C07D	277/02		X
		BF WO 95/15316	Jun 08, 1995	WIPO	C07D	231/12		X
		BG WO 95/18799	Jul 13, 1995	WIPO	C07D	307/58		X

OTHER DOCUMENTS (Including author, title, date, pertinent pages, etc.)

	CZ	Barkin (1997). Cancer pain treatment insights. Pharmacotherapy 17(2), pp. 397-398.
	DA	Burger & Wachter (1998). Hunnius - Pharmazeutisches Wörterbuch (in German; believed to translate as "Pharmaceutical Dictionary"), 8th Edition. Walter de Gruyter. Berlin, New York, pp. 278, 854, 954, 1109. English translation provided.
	DB	Lipsky (1999). COX-2 specific inhibitors: basic science and clinical implications. Amer. J. Med. 106(5B), pp. 1S-2S.
	DC	Raskin (1999). Gastrointestinal effects of nonsteroidal anti-inflammatory activity. Amer. J. Med. 106(5B), pp. 3S-12S.
	DD	Radebaugh & Ravin (1995). Preformulation. In Remington's Pharmacy, 19th edition, Vol. II, Chap. 83. Mack Publishing Group, p. 1449.
	DE	Serafin (1996). Drugs used in the treatment of asthma. In Goodman & Gilman's Pharmacological Basis of Therapeutics, 9th edition, Chap. 28. McGraw-Hill, p. 665.
	DF	Voigt (1993). Pharmazeutische Technologie für Studium und Beruf (in German; believed to translate as "Pharmaceutical Technology for the Classroom and Professional Applications"), 7th edition. Ulstein Mosby GmbH & Co. KG Berlin, pp. 40-43, 119, 210-212, 231-238. English translation provided.
	DG	Whelton (1999). Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Amer. J. Med. 106(5B), pp. 13S-24S.

Examiner

Date Considered

* Examiner, Initial if citation considered, whether or not citation is in conformance with MPEP §609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

C-3169/1/US

09/451,641

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant

Gao, D. et al.

Filing Date

November 30, 1999

Group No.

1615

U.S. PATENT DOCUMENTS

Examiner Initial*		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
	AC	5,869,096	Feb 9, 1999	Barclay et al.	424	468	Dec 9, 1994
	AD	5,756,529	May 26, 1998	Isakson et al.	514	406	
	AE	5,633,272	May 27, 1997	Talley et al.	514	378	
	AF	5,474,784	Dec 12, 1995	Stevens et al.	424	456	
	AG	5,342,624	Aug 30, 1994	McNeill et al.	424	451	
	AH	4,866,848	Sep 12, 1989	Conte et al.	424	466	
	AI	4,681,755	Jul 21, 1987	Colombo et al.	424	486	

FOREIGN PATENT DOCUMENTS

Examiner Initial*		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
	BC	WO 97/44028	Nov 27, 1997	WIPO	A61K	31/365		X
	BD	WO 99/09988	Mar 4, 1999	WIPO	A61K	31/54		X

OTHER DOCUMENTS (Including author, title, date, pertinent pages, etc.)

	CD	Abdou (1989). Dissolution, Bioavailability and Bioequivalence, pp. 58-66, 457-458. Mack Publishing Co.
	CE	American Pharmaceutical Association (1986). Handbook of Pharmaceutical Excipients, pp. 1-2, 5, 9-11, 26-33, 39-40, 45-48, 53-58, 93-98, 113-115, 119-121, 123-126, 128-129, 134-135, 138-140, 153-162, 166-169, 177-183, 209-211, 214-215, 234-239, 261-262, 266-268, 271-272, 275-278, 284-293, 298-300, 304-308.
	CF	Anon. (1997). Drugs of the Future 22(7). Section headed "Pharmacokinetics", p. 713.
	CG	Ayanoglu (1981). Biyofarmasötik ve Klinik Farmakokinetik (In Turkish; believed to translate as "Biopharmaceutics and Clinical Pharmacokinetics"), pp. 35-36. No English translation available.
	CH	Bandelin (1989). Compressed tablets by wet granulation. In Lieberman et al. (ed.) Pharmaceutical Dosage Forms: Tablets, 2nd ed., Vol. 1, pp. 131-193. Marcel Dekker.
	CI	Banker & Anderson (1986). Tablets. In Lachman et al. (ed.) The Theory and Practice of Industrial Pharmacy, pp. 293-373. Lea & Febiger.
	CJ	DiSanto (1985). Bioavailability and Bioequivalency Testing. Chap. 77 in Remington's Pharmaceutical Sciences, 17th ed., pp. 1424-1431. Mack Publishing Co.
	CK	Geçgil (1991). Farmasötik Teknolojiye Başlangıç (In Turkish; believed to translate as "Introduction to Pharmaceutical Technology"), pp. 346-348. No English translation available.
	CL	Güven (1979). İlaç Endüstrisi Teknolojisi (In Turkish; believed to translate as "Drug Industry Technology"), pp. 67-81. No English translation available.
	CM	Hubbard et al. (1998). Efficacy, tolerability and safety of celecoxib in osteoarthritis. American College of Rheumatology 62nd National Scientific Meeting, San Diego, California, November 1998.
	CN	Igzü (date unknown). Genel ve Endüstriyel Farmasötik Teknoloji (In Turkish; believed to translate as "General and Industrial Pharmaceutical Technology"), Vol. 1, pp. 367-382. No English translation available.
	CO	Igzü (1983). Genel - Endüstriyel Farmasötik Teknoloji - II (In Turkish; believed to translate as "General and Industrial Pharmaceutical Technology - II"), pp. 211-241. No English translation available.

Examiner

Date Considered

6/27/00

*Examiner Initial if citation considered, whether or not citation is in conformance with MPEP §609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

C-3169/1/US

09/451,641

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant

Gao, D. *et al.*

Filing Date

November 30, 1999

Group No.

1615

OTHER DOCUMENTS (Including author, title, date, pertinent pages, etc.)

- | | |
|----|--|
| CP | Karim <i>et al.</i> (1997). SC-58635 (celecoxib): a highly selective inhibitor of cyclooxygenase-2. Disposition kinetics in man and identification of its major CYP450 isozyme in its biotransformation. <i>Pharmaceutical Research</i> 14, p. S-617, Abstr. 3469. |
| CQ | Kayaalp (date unknown). <i>Tibbi Farmakoloji</i> (In Turkish; believed to translate as "Medicinal Pharmacology"), Vol. 1, pp. 27-28 and Vol. 2, p. 1050. No English translation available. |
| CR | Lane (1997). Pain management in osteoarthritis: the role of COX-2 inhibitors. <i>Journal of Rheumatology</i> 24 (Supp. 49), 20-24. |
| CS | Parnham (1996). Inflammation: mechanisms and therapeutics. <i>Drug News & Perspectives</i> 9, 631-639. |
| CT | Peck <i>et al.</i> (1989). Tablet formulation and design. In Lieberman <i>et al.</i> (ed.) <i>Pharmaceutical Dosage Forms: Tablets</i> , 2nd ed., Vol. 1, pp. 75-130. Marcel Dekker. |
| CU | Proudfoot (1990). Factors influencing bioavailability: factors influencing drug absorption from the gastrointestinal tract. In Aulton (ed.) <i>Pharmaceutics: The Science of Dosage Form Design</i> , p. 156. |
| CV | Rubinstein (1990). Tablets. In Aulton (ed.) <i>Pharmaceutics: The Science of Dosage Form Design</i> , pp. 304-321. |
| CW | Shangraw (1989). Compressed tablets by direct compression. In Lieberman <i>et al.</i> (ed.) <i>Pharmaceutical Dosage Forms: Tablets</i> , 2nd ed., Vol. 1, pp. 195-246. Marcel Dekker. |
| CX | Wadke <i>et al.</i> (1989). Preformulation testing. In Lieberman <i>et al.</i> (ed.) <i>Pharmaceutical Dosage Forms: Tablets</i> , 2nd ed., Vol. 1, pp. 1-73. Marcel Dekker. See pp. 5, 47-48. |
| CY | Welling <i>et al.</i> (1991). <i>Pharmaceutical Bioequivalence</i> , pp. 413-414. Marcel Dekker. |

Examiner

Date Considered

12/7/99

* Examiner Initial if citation considered, whether or not citation is in conformance with MPEP §609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.